These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 7660130)

  • 1. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
    Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
    Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of transcription elongation by the VHL tumor suppressor protein.
    Duan DR; Pause A; Burgess WH; Aso T; Chen DY; Garrett KP; Conaway RC; Conaway JW; Linehan WM; Klausner RD
    Science; 1995 Sep; 269(5229):1402-6. PubMed ID: 7660122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
    Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.
    Schoenfeld AR; Davidowitz EJ; Burk RD
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8507-12. PubMed ID: 10900011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
    Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
    J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
    Feldman DE; Thulasiraman V; Ferreyra RG; Frydman J
    Mol Cell; 1999 Dec; 4(6):1051-61. PubMed ID: 10635329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
    Tsuchiya H; Iseda T; Hino O
    Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
    Takagi Y; Pause A; Conaway RC; Conaway JW
    J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
    Pioli PA; Rigby WF
    J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
    Kishida T; Stackhouse TM; Chen F; Lerman MI; Zbar B
    Cancer Res; 1995 Oct; 55(20):4544-8. PubMed ID: 7553625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
    Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
    Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von Hippel-Lindau tumour suppressor protein: new perspectives.
    Ohh M; Kaelin WG
    Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
    Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
    Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.